Ovid Therapeutics Inc.
OVID· Nasdaq
Released Mar 18, 2026, before the open
10-K filed Mar 18, 2026, 77 days after period end · 0001628280-26-019438
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $718.00K | $76.00K | $142.00K | $46.28K |
| Net Income | $9.66M |
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
| -$9.25M |
| -$15.32M |
| -$11.50M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.